Recent advances in protien-tyrosine-phosphatase 1B (PTP1B) inhibitors for the treatment of type 2 diabetes and obesity

Drugs of the Future

Volumn 29, Issue 12, 2004, Pages 1245-1259

  Liu, Gang ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; LEPTIN; PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR;

CELL MEMBRANE PERMEABILITY; DRUG INHIBITION; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW;

EID: 13644249881     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2004.029.12.851854     Document Type: Review

References (85)

1. Zimmet, P., Alberti, K.G.M.M., Shaw, J. Global and societal implications of the diabetes epidemic. Nature 2001, 414: 782-7.
2. Wild, S., Roglic, G., Green, A., Sicree, R., King, H. Global prevalence of diabetes. Diabetes Care 2004, 27: 1047-53.
3. Must, A., Spadano, J., Coakley, E.H., Field, A.E., Colditz, G., Dietz, W.H. The disease burden associated with overweight and obesity. JAMA - J Am Med Assoc 1999, 282: 1523-9.
4. Hogan, P., Dall, T., Nikolov, P. Economic costs of diabetes in the US in 2002. Diabetes Care 2003, 26: 917-32.
5. Statistics related to overweight and obesity. NIH publication No.03-4158, July 2003.
6. Beck-Nielsen, H., Henriksen, J.E., Vaag, A., Hother-Nielsen, O. Pathophysiology of non-insulin-dependent diabetes mellitus (NIDDM). Diabetes Res Clin Pract 1995, 28(Suppl.): S13-25.
7. Kahn, B.B., Flier, J.S. Obesity and insulin resistance. J Clin Invest 2000, 106: 473-81.
8. Maffei, M., Halaas, J., Ravussin, E. et al. Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995, 1: 1155-61.
9. Hunter, T. Signaling - 2000 and beyond. Cell 2000, 100: 113-27.
10. Hunter, T. Protein kinases and phosphatases: The yin and yang of protein phosphorylation and signaling. Cell 1995, 80: 225-36.
11. Tonks, N.K., Neel, B.G. Combinatorial control of the specificity of protein tyrosine phosphatases. Curr Opin Cell Biol 2001, 13: 182-95.
12. Zabolotny, J.M., Haj, F.G., Kim, Y.B. et al. Transgenic overexpression of protein-tyrosine phosphatase 1B in muscle causes insulin resistance, but overexpression with leukocyte antigen-related phosphatase does not additively impair insulin action. J Biol Chem 2004, 279: 24844-51.
13. Xie, L., Lee, S.-Y., Andersen, J.N. et al. Cellular effects of small molecule PTP1B inhibitors on insulin signaling. Biochemistry 2003, 42: 12792-804.
14. Echebly, M., Payette, P., Michaliszyn, E. et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein-tyrosine phosphatase-1B gene. Science 1999, 283: 1544-8.
15. Klaman, L.D., Boss, O., Peroni, O.D. et al. Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol Cell Biol 2000, 20: 5479-89.
16. Cheng, A., Uetani, N., Simoncic, P.D. et al. Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B. Dev Cell 2002, 2: 497-503.
17. Zabolotny, J.M., Bence-Hanulec, K.K., Stricker-Krongrad, A. et al. PTP1B regulates leptin signal transduction in vivo. Dev Cell 2002, 2: 489-95.
18. Ahima, R.S., Flier, U.S. Leptin. Annu Rev Physiol 2000, 62: 413-37.
19. Woods, S.C., Lotter, E.C., McKay, L.D., Porte, D. Jr. Chronic intracerebroventricular infusion of insulin reduces food intake and body weight of baboons. Nature 1979, 282: 503-5.
20. Brüning, J.C., Gautam, D., Burks, D.J. et al. Role of brain insulin receptor in control of body weight and reproduction. Science 2000, 289: 2122-5.
21. Niswender, K.D., Schwartz, M.W. Insulin and leptin revisited: Adiposity signals with overlapping physiological and intracellular signaling capabilities. Front Neuroendocrinol 2003, 24: 1-10.
22. Niswender, K.D., Morrison, C.D., Clegg, D.J. et al. Insulin activation of phosphatidylinositol 3-kinase in the hypothalamic arcuate nucleus: A key mediator of insulin-induced anorexia. Diabetes 2003, 52: 227-31.
23. Zinker, B.A., Rondinone, C.M., Trevillyan, J.M. et al. PTP1B antisense lowers PTP1B protein, normalizes blood glucose and improves insulin sensitivity in diabetic mice. Proc Natl Acad Sci USA 2002, 99: 11357-62.
24. Bush, E.N., Shapiro, R., Clampit, J. et al. Treatment of Zucker diabetic fatty rats with antisense oligonucleotides to protein tyrosine phosphatase 1B for 5 weeks halts development of diabetes. Diabetes 2001, 50(Suppl. 2): A81.
25. Liu, G. Technology evaluation: ISIS-113715, ISIS. CurrOpin Mol Ther 2004, 6: 331-6.
26. Dubé, N., Tremblay, M.L. Beyond the metabolic function of PTP1B. Cell Cycle 2004, 3: 550-3.
27. Dubé, N., Cheng, A., Tremblay, M.L. The role of protein tyrosine phosphatase 1B in Ras signaling. Proc Natl Acad Sci USA 2004, 101: 1834-9.
28. Jackson, M.D., Denu, J.M. Molecular reactions of protein phosphatases - Insights from structure and chemistry. Chem Rev 2001, 101: 2313-40.
29. Denu, J.M., Lohse, D.L., Vijayalakshmi, J., Saper, M.A., Dixon, J.E. Visualization of intermediate and transition-state structures in protein-tyrosine phosphatase catalysis. Proc Natl Acad Sci USA 1996, 93: 2493-8.
30. Jia, Z., Barford, D., Flint, A., Tonks, N. K. Structural basis for phosphotyrosine peptide recognition by protein tyrosine phosphatase 1B. Science 1998, 268: 1754-8.
31. Puius, Y.A., Zhao, Y., Sullivan, M., Lawrence, D.S., Almo, S.C., Zhang, Z.-Y. Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase 1B: A paradigm for inhibitor design. Proc Natl Acad Sci USA 1997, 94: 13420-5.
32. Salmeen, A., Andersen, J.N., Myers, M.P., Tonks, N.K., Barford, D. Molecular basis for the dephosphorylat/on of the activation segment of the insulin receptor by protein tyrosine phosphatase 1B. Mol Cell 2000, 6: 1401-2.
33. Asante-Appiah, E., Ball, K., Bateman, K. et al. The YRD motif is a major determinant of substrate and inhibitor specificity in T-cell protein-tyrosine phosphatase. J Biol Chem 2001, 276: 26036-43.
34. Jia, Z., Ye, Q., Dinaut, A.N. et al. Structure of protein tyrosine phosphatase 1B in complex with inhibitors bearing two phosphotyrosine mimetics. J Med Chem 2001, 44: 4584-94.
35. Peters, G.H., Iversen, L.F., Branner, S. et al. Residue 259 is a key determinant of substrate specificity of protein-tyrosine phosphatases 1B and α. J Biol Chem 2000, 275: 18201-9.
36. Salmeen, A., Andersen, J.N., Myers, M.P. et al. Redox regulation of protein tyrosine phosphatase 1B involves a sulphenylamide intermediate. Nature 2003, 423: 769-73.
37. van Montfort, R.L., Congreve, M., Tisi, D., Carr, R., Jhoti, H. Oxidation state of the active-site cysteine in protein tyrosine phosphatase 1B. Nature 2003, 423: 773-7.
38. You-Ten, K.E., Muise, E.S., Itié, A. et al. Impaired bone marrow microenvironment and immune function in T cell protein tyrosine phosphatase-deficient mice. J Exp Med 1997, 186: 683-93.
39. Iversen, L.F., Møller, K.B., Pedersen, A.K. et al. Structure determination of T cell protein tyrosine phosphatase. J Biol Chem 2002, 277: 19982-90.
40. Liu, G., Trevillyan, J.M. Protein tyrosine phosphatase 1B as a target for the treatment of impaired glucose tolerance and type 2 diabetes. Curr Opin Invest Drugs 2002, 3: 1608-16.
41. a) van Huijsduijnen, R.H., Sauer, W.H.B., Bombrun, A., Swinnen, D. Prospects for inhibitors of protein tyrosine phosphatase 1B as antidiabetic drugs. J Med Chem 2004, 47: 4142-6.
42. b) Taylor, S.D., Hill, B. Recent advances in protein tyrosine phosphatase 1B inhibitors. Exp Opin Invest Drugs 2004, 13: 199-214.
43. c) Liu, G. Protein tyrosine phosphatase 1B inhibition: Opportunities and challenges. Curr Med Chem 2003, 10: 1407-21.
44. d) Harley, E.A., Levens, N. Protein tyrosine phosphatase 1B inhibitors for the treatment of type 2 diabetes and obesity: Recent advances. Curr Opin Invest Drugs 2003, 4: 1179-89.
45. e) Johnson, T.O., Ermolieff, J., Jirousek, M.R. Protein tyrosine phosphatase 1B inhibitors for diabetes. Nat Rev Drug Discov 2002, 1: 696-709.
46. f) Møller, N.P.M., Iversen, L.F., Andersen, H.S., McCormack, J.G. Protein tyrosine phosphatases (PTPs) as drug targets: Inhibition of PTP1B for the treatment of diabetes. Curr Opin Drug Discov Devel 2000, 3: 527-40.
47. Skorey, K.I., Kennedy, B.P., Friesen, R.W., Ramachandran, C. Development of a robust scintillation proximity assay for protein tyrosine phosphatase 1B using the catalytically inactive (C215S) mutant. Anal Biochem 2001, 291: 269-78.
48. Shen, K., Keng, Y.-F., Wu, L., Guo, X.-L, Lawrence, D.S., Zhang, Z.-Y. Acquisition of a specific and potent PTP1B inhibitor from a novel combinatorial library and screening procedure. J Biol Chem 2001, 276: 47311-9.
49. Asante-Appiah, E., Patel, S., Dufresne, C. et al. The structure of PTP-1B in complex with a peptide inhibitor reveals an alternative binding mode for bisphosphonates. Biochemistry 2002, 41: 9043-51.
50. Sun, J.-P., Fedorov, A.A., Lee, S.-Y. et al. Crystal structure of PTP1B complexed with a potent and selective bidentate inhibitor. J Biol Chem 2003, 278: 12406-14.
51. Dufresne, C., Roy, P., Wang, Z. et al. The development of potent non-peptidic PTP-1B inhibitors. Bioorg Med Chem Lett 2004, 14: 1039-42.
52. Lau, C.K., Bayly, C.I., Gauthier, J.Y. et al. Structure based design of a series of potent and selective non peptidic PTP-1B inhibitors. Bioorg Med Chem Lett 2004, 14: 1043-8.
53. Scapin, G., Patel, S.B., Becker, J.W., Wang, Q., Desponts, C., Waddleton, D. The structural basis for the selectivity of benzotriazole inhibitors of PTP1B. Biochemistry 2003, 42: 11451-9.
54. Li, X., Bhandari, A., Holmes, C.P., Szardenings, A.K. α,α-Difluoro-β-ketophosphonates as potent inhibitors of protein tyrosine phosphatase 1B. Bioorg Med Chem Lett 2004, 14: 4301-6.
55. Andersen, H.S., Iversen, L.F., Jeppesen, C.B. et al. 2-(Oxalylamino)- benzoic acid is a general, competitive inhibitor of protein-tyrosine phosphatases. J Biol Chem 2000, 275: 7101-8.
56. Iversen, L.F., Andersen, H.S., Branner, S. et al. Structure-based design of a low molecular weight, nonphosphorus, nonpeptide, and highly selective inhibitor of protein-tyrosine phosphatase 1B. J Biol Chem 2000, 275: 10300-7.
57. Andersen, H.S., Olsen, O.H., Iversen, L.F. et al. Discovery and SAP of a novel selective and orally bioavailable nonpeptide classical competitive inhibitor class of protein-tyrosine phosphatase 1B. J Med Chem 2002, 45: 4443-59.
58. Iversen, L.F., Andersen, H.S., Møller, K.B. et al. Steric hindrance as a basis for structure-based design of selective inhibitors of protein-tyrosine phosphatases. Biochemistry 2001, 40: 14812-20.
59. Andersen, H.S., Hansen, T.K., Lau J. et al. (Novo Nordisk A/S) Modulators of protein tyrosine phosphatases (PTPs). WO 0204459.
60. Hansen, T.K., Iversen, L.F., Lau, J. et al. Potent non-peptide protein-tyrosine phosphatase inhibitors. 223rd ACS Natl Meet (April, Orlando) 2002, Abst MEDI-003.
61. Szczepankiewicz, B.G., Liu, G., Hajduk, P.J. et al. Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy. J Am Chem Soc 2003, 125: 4087-96.
62. Liu, G, Szczepankiewicz, B.G., Pei, Z. et al. Discovery and structure-activity relationship of oxalylarylaminobenzoic acids as inhibitors of protein tyrosine phosphatase 1B. J Med Chem 2003, 46:2093-103.
63. Xin, Z., Oost, T.K., Abad-Zapatero, C. et al. Potent, selective inhibitors of protein tyrosine phosphatase 1B. Bioorg Med Chem Lett 2003, 13: 1887-90.
64. Liu, G., Xin, Z., Liang, H. et al. Selective protein tyrosine phosphatase 1B inhibitors: Targeting the second phosphotyrosine binding site with non-carboxylic acid-containing ligands. J Med Chem. 2003, 46: 3437-40.
65. Bleasdale, J.E., Ogg, D., Palazuk, B.J. et al. Small molecule peptidomimetics containing a novel phosphotyrosine bioisostere inhibit protein tyrosine phosphatase 1B (PTP1B) and augment insulin action. Biochemistry 2001, 40: 5642-54.
66. Larsen, S.D., Barf, T., Liljebris, C. et al. Synthesis and biological activity of a novel class of small molecular weight peptidomimetic competitive inhibitors of protein tyrosine phosphatase 1B. J Med Chem 2002, 45: 598-622.
67. Liljebris, C., Larsen, S.D., Ogg, D., Palazuk, B.J., Bleasdale, J.E. Investigation of potential bioisosteric replacement for the carboxyl groups of peptidomimetic inhibitors of protein tyrosine phosphatase 1B: Identification of a tetrazole-containing inhibitor with cellular activity. J Med Chem 2002, 45: 1785-98.
68. Larsen, S.D., Stevens, F.C., Lindberg, T.J. et al. Modification of the N-terminus of peptidomimetic protein tyrosine phosphatase 1B (PTP1B) inhibitors: Identification of analogues with cellular activity. Bioorg Med Chem Lett 2003, 13: 971-5.
69. Pei, Z., Li, X., Liu, G. et al. Discovery and SAR of novel, potent and selective protein tyrosine phosphatase 1B inhibitors. Bioorg Med Chem Lett 2003, 13: 3129-32.
70. Wrobel, J., Sredy, J., Moxham, C. et al. PTP1B inhibition and antihyperglycemic activity of novel 11-arylbenzo[b]naphtho[2,3-d]furans and 11-arylbenzo[b]naphtho[2,3-d]thiophenes. J Med Chem 1999, 42: 3199-202.
71. Pei, Z., Zinker, B.A., Gum, R.J. et al. (2R)-2-(2′,6′- Dichloro-4′-dibenzo(b,d)furan-4″-ylphenoxy)-3-phenylpropanoic acid (A-321842) as a protein tyrosine phosphatase 1B (PTP1B) inhibitor with anti-diabetic effects in ob/ob mice. Diabetes 2001, 50(S1): 1524-P, A401.
72. PTP-112, Drug Report, Investigational Drugs Database, www. Iddb3.com. (April 9, 2003).
73. Liu, G., Xin, Z., Pei, Z. et al. Fragment screening and assembly: A highly efficient approach to a selective and cell active protein tyrosine phosphatase 1B inhibitor. J Med Chem 2003, 46: 4232-5.
74. Xin, Z., Liu, G., Abad-Zapatero, C. et al. Identification of a monoacid-based, cell permeable, selective inhibitor of protein tyrosine phosphatase 1B. Bioorg Med Chem Lett 2003, 13: 3947-50.
75. Erlason, D.A., McDowell, R.S., He, M.M. et al. Discovery of a new phosphotyrosine mimetic for PTP1B using breakaway tethering. J Am Chem Soc 2003, 125: 5602-3.
76. Wang, J., Rideout, D., Ramnarayan, K. et al. Organosulfur inhibitors of protein phosphatase. WO 03032916.
77. Inaba, T., Ikemoto, T., Maegawa, H., Kashiwagi, A. (Japan Tobacco Inc.) Azole compound and medical use thereof. WO 03048140.
78. Huang, P., Ramphal, J., Wei, J. et al. Structure-based design and discovery of novel inhibitors of protein tyrosine phosphatases. Bioorg Med Chem 2003, 11: 1835-49.
79. Liljebris, C., Marinsson, J., Tedenborg, L. Synthesis and biological activity of a novel class of pyridazine analogues as non-competitive reversible inhibitors of protein tyrosine phosphatase 1B. Bioorg Med Chem 2002, 10: 3197-212.
80. Tjernberg, A., Hallen, D., Schultz, J. et al. Mechanism of action of pyridazine analogues on protein tyrosine phosphatase 1B (PTP1B). Bioorg Med Chem Lett 2004, 14: 891-5.
81. Guertin, K.R., Setti, L., Qi, L. et al. Identification of a novel class of orally active pyrimido[5,4-3]triazine-5,7-diamine-based hypoglycemic agents with protein tyrosine phosphatase 1B inhibitory activity. Bioorg Med Chem Lett 2003, 13: 2895-8.
82. Thakkar, K.C., Berthel, S., Bose, J. et al. Diaminopyrrolo-quinazolines 2: Novel and highly selective protein tyrosine phosphatase 1B inhibitors. 227th ACS Natl Meet (March 28-April 1, Anaheim) 2004, Abst MEDI-049.
83. Thakkar, K.C., Bose, J., Banner, B. et al. Diaminopyrrolo-quinazolines 3: Novel and highly selective protein tyrosine phosphatase 1B inhibitors. 227th ACS Natl Meet (March 28-April 1, Anaheim) 2004, Abst MEDI-053.
84. Wiesmann, C., Barr, K.J., Kung, J. et al. Allosteric inhibition of protein tyrosine phosphatase 1B. Nat Struct Mol Biol 2004, 11: 730-7.
85. Bombrun, A., Gerber, P., Church, D. Preparation of oxindole hydrazide modulators of protein tyrosine phosphatases (PTPs). WO 03037328.